219 related articles for article (PubMed ID: 32555504)
21. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
22. Insight into cofactor recognition in arylamine N-acetyltransferase enzymes: structure of Mesorhizobium loti arylamine N-acetyltransferase in complex with coenzyme A.
Xu X; Li de la Sierra-Gallay I; Kubiak X; Duval R; Chaffotte AF; Dupret JM; Haouz A; Rodrigues-Lima F
Acta Crystallogr D Biol Crystallogr; 2015 Feb; 71(Pt 2):266-73. PubMed ID: 25664736
[TBL] [Abstract][Full Text] [Related]
23. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.
Minchin RF; Butcher NJ
BMC Genomics; 2018 Jul; 19(1):513. PubMed ID: 29969986
[TBL] [Abstract][Full Text] [Related]
24. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
25. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.
Tiang JM; Butcher NJ; Minchin RF
Biochem Biophys Res Commun; 2010 Feb; 393(1):95-100. PubMed ID: 20100460
[TBL] [Abstract][Full Text] [Related]
26. Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study.
Dairou J; Atmane N; Rodrigues-Lima F; Dupret JM
J Biol Chem; 2004 Feb; 279(9):7708-14. PubMed ID: 14672957
[TBL] [Abstract][Full Text] [Related]
27. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
Tiang JM; Butcher NJ; Minchin RF
Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2.
Walraven JM; Doll MA; Hein DW
J Pharmacol Exp Ther; 2006 Oct; 319(1):369-75. PubMed ID: 16829624
[TBL] [Abstract][Full Text] [Related]
29. Arylamine
Li P; Butcher NJ; Minchin RF
Mol Pharmacol; 2019 Nov; 96(5):573-579. PubMed ID: 31444237
[TBL] [Abstract][Full Text] [Related]
30.
Stepp MW; Salazar-González RA; Hong KU; Doll MA; Hein DW
J Oncol; 2019; 2019():3860426. PubMed ID: 31531019
[TBL] [Abstract][Full Text] [Related]
31. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
32. Arylamine
Salazar-González RA; Doll MA; Hein DW
Front Pharmacol; 2022; 13():797469. PubMed ID: 35153780
[TBL] [Abstract][Full Text] [Related]
33. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
34. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
35. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.
Sim E; Lack N; Wang CJ; Long H; Westwood I; Fullam E; Kawamura A
Toxicology; 2008 Dec; 254(3):170-83. PubMed ID: 18852012
[TBL] [Abstract][Full Text] [Related]
36. Human
Hein DW; Doll MA; Habil MR
Front Pharmacol; 2022; 13():821133. PubMed ID: 35281898
[TBL] [Abstract][Full Text] [Related]
37. Human acetyltransferase polymorphisms.
Grant DM; Hughes NC; Janezic SA; Goodfellow GH; Chen HJ; Gaedigk A; Yu VL; Grewal R
Mutat Res; 1997 May; 376(1-2):61-70. PubMed ID: 9202739
[TBL] [Abstract][Full Text] [Related]
38. Stable Isotope Tracing Reveals an Altered Fate of Glucose in
Wise JTF; Yin X; Ma X; Zhang X; Hein DW
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107601
[TBL] [Abstract][Full Text] [Related]
39. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.
Goodfellow GH; Dupret JM; Grant DM
Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727
[TBL] [Abstract][Full Text] [Related]
40. A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis.
Sinclair J; Sim E
Biochem Pharmacol; 1997 Jan; 53(1):11-6. PubMed ID: 8960058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
